ALAN SWANN to Depressive Disorder, Treatment-Resistant
This is a "connection" page, showing publications ALAN SWANN has written about Depressive Disorder, Treatment-Resistant.
Connection Strength
0.839
-
High-order brain interactions during ketamine-induced state changes: A functional marker of response in late-life treatment-resistant depression? Transl Psychiatry. 2026 Jul 04; 16(1).
Score: 0.210
-
Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial. Neuropsychopharmacology. 2023 10; 48(11):1586-1593.
Score: 0.168
-
Replication of distinct trajectories of antidepressant response to intravenous ketamine. J Affect Disord. 2023 01 15; 321:140-146.
Score: 0.163
-
Identification of an optimal dose of intravenous ketamine for late-life treatment-resistant depression: a Bayesian adaptive randomization trial. Neuropsychopharmacology. 2022 04; 47(5):1088-1095.
Score: 0.153
-
Distinct trajectories of antidepressant response to intravenous ketamine. J Affect Disord. 2021 05 01; 286:320-329.
Score: 0.145